Livzon Pharmaceutical Group Inc 2022 AR2
The report highlights Livzon Pharmaceutical Group Inc.'s financial and operational performance for the fiscal year 2022. The company achieved an operating income of RMB 12,629.58 million, representing a year-on-year increase of 4.69%, and a net profit attributable to shareholders of RMB 1,909.39 million. Key achievements include the emergency use approval of its Recombinant SARS-CoV-2 Fusion Protein Vaccine (LIKANG) and the marketing approval of Tocilizumab Injection. Additionally, the company made charitable donations of approximately RMB 9.98 million and continued its commitment to green development, aiming for carbon neutrality by 2055.
Company: Livzon Pharmaceutical Group Inc
Sector: Manufacturing
Country: China
Year: 2022
Type: AR2
Pages: 474
Back to company
Livzon Pharmaceutical Group Inc
Annual Report
The report highlights Livzon Pharmaceutical Group Inc.'s financial and operational performance for the fiscal year 2022. The company achieved an operating income of RMB 12,629.58 million, representing a year-on-year increase of 4.69%, and a net profit attributable to shareholders of RMB 1,909.39 million. Key achievements include the emergency use approval of its Recombinant SARS-CoV-2 Fusion Protein Vaccine (LIKANG) and the marketing approval of Tocilizumab Injection. Additionally, the company made charitable donations of approximately RMB 9.98 million and continued its commitment to green development, aiming for carbon neutrality by 2055.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Net Zero Target
Employees